Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in lupus nephritis (LN).
CEO Fred Aslan told the Clinical Trials Arena that the company is currently enrolling patients on the trial with hopes to dose the first patient within H1 2024.
Read the full article here.
SDBJ: Artiva Bio Soaring on Focus Shift from Oncology to Autoimmune Disease Artiva Biotherapeutics was featured in the San Diego Business Journal highlighting the Company’s strategic transition into autoimmune disease and the FDA Fast Track Designation for AlloNK® in rheumatoid arthritis. The story outlines how AlloNK is designed for outpatient use and underscores the significant...
Inside Precision Medicine spoke with Artiva’s Chief Medical Officer, Dr. Subhashis Banerjee, about our clinical development approach for AlloNK® in autoimmune disease. In the Q&A, Dr. Banerjee outlines how we are advancing AlloNK® through a parallel trial strategy, conducting both a Phase 2a basket trial and an investigator-initiated study in the community setting. These trials...
In this interview with Pharmaceutical Manufacturer, Artiva CEO Fred Aslan, M.D., discusses the unique advantages of natural killer (NK) cell therapies and the company’s mission to bring scalable, off-the-shelf treatments to patients with autoimmune diseases. The Q&A explores how Artiva’s AlloNK® platform—comprising non-genetically modified, cryopreserved NK cells combined with disease-targeting monoclonal antibodies—could offer a more...